Ducore J, et al. - This first dose-escalation study of eptacog beta (recombinant human FVIIa, rhFVIIa) was planned to assess the safety, pharmacokinetics, and laboratory pharmacodynamics of 3 doses of rhFVIIa in non-bleeding patients with congenital haemophilia A or B with or without inhibitors. Findings revealed that eptacog beta at doses of 25, 75, and 225 μg/kg was pharmacodynamically active and well tolerated in non-bleeding patients with congenital haemophilia A or B.